Skip to main content

Table 5 Effect of Doxorubicin (DOX) and different treatments of AHE on cardiac enzymatic antioxidant levels and GSH profile

From: Acacia hydaspica R. Parker prevents doxorubicin-induced cardiac injury by attenuation of oxidative stress and structural Cardiomyocyte alterations in rats

Group

GSH (μM/g tissue)

GR (nM/min/mg protein)

GST (nM/min/mg protein)

γ-GT (nM/min/mg Protein)

GPx (nM/min/mg Protein)

Control

20.55 ± 0.280b

154.9 ± 0.96b

148.6 ± 0.665b

303.5 ± 0.811b

122.4 ± 0.639b

DOX

12.36 ± 0.490a

108.7 ± 1.095a

108.9 ± 1.105a

98.54 ± 1.106a

63.20 ± 1.027a

AHE alone

20.66 ± 0.237b

155.6 ± 0.439b

148.4 ± 0.815b

306.9 ± 0.401b

122.9 ± 0.285b

DOX + AHE (200)

14.37 ± 0.38a,b*,d

122.9 ± 1.14a,b,d

122.8 ± 0.984a,b,d

188.8 ± 0.095a,b,d

85.37 ± 0.540a,b,d

DOX + AHE (400)

18.59 ± 0.44a*,b, c

141.2 ± 1.00a,b,c

140.6 ± 0.723a,b,c

291.6 ± 0.69a,b,c

114.1 ± 0.845a,b,c

DOX + Sily

18.77 ± 0.360b

140.3 ± 1.55a,b

139.2 ± 0.4623a,b

289.0 ± 0.68a,b

115.9 ± 1.290a**,b

  1. Values expressed as mean ± SEM
  2. aSignificance at p < 0.0001 Vs. control group
  3. bSignificance at p < 0.0001 Vs. Doxorubicin (DOX) group
  4. cSignificance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group
  5. dSignificance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group
  6. *, **Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin